This study provides experimental evidence for the inhibitory effect of LXR against the inflammatory response and lipid accumulation via inhibition of the NF-κB signaling pathway in RPE cells and in an animal model of advanced CNV, supporting the therapeutic effects of LXR agonist TO in AMD and providing insight into the mechanisms underlying these effects. This evidence concerns the gene NFKB1 and age-related macular degeneration.